[New insights in pathogenesis and therapy of sporadic inclusion body myositis (s-IBM)].
Sporadic inclusion body myositis (s-IBM) is a chronic progressive inflammatory myopathy which occurs preferentially in older patients. Histologic hallmarks are rimmed vacuoles and eosinophilic cytoplasmatic inclusions. The etiology is still unknown, but different pathogenetic mechanisms such as slow virus infection, autoimmunopathogenesis, myonuclear alterations, and mitochondrial defects have been implicated. A relation to neurodegenerative disorders and prion diseases has also been suggested. There is a poor response if any to immunosuppressive therapy. Stabilization of disease progression was shown only by intravenous immunoglobulin (IVIG) therapy. Future findings in the field of s-IBM pathogenesis may result in better therapeutic options.
Friedrich-Baur-Institut, Medizinische Klink, Klinikum der Ludwig-Maximilians-Universität, Ziemssenstr. 1a, 80336 München. Maggie.Walter@lrz.uni-muenchen.de
M C
MC
Walter
H
H
Lochmüller
B
B
Schlotter
P
P
Reilich
W
W
Müller-Felber
D
D
Pongratz
D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003459:Crystallins / Q000235:genetics*; D004359:Drug Therapy, Combination; D005786:Gene Expression Regulation / Q000235:genetics / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006801:Humans; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018995:Myosin Heavy Chains / Q000235:genetics; D018979:Myositis, Inclusion Body / Q000209:etiology* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016328:NF-kappa B / Q000276:immunology; D026741:Physical Therapy Modalities
D000961:Antilymphocyte Serum; D003459:Crystallins; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D018995:Myosin Heavy Chains; D008727:Methotrexate